The Company is administered by a Board of Directors and run by an Executive Committee, whose respective functions and responsibilities are clearly defined in the Corporate Governance Charter.
To enhance the overall effectiveness of the Board by ensuring focus, oversight and monitoring of sensitive areas, the Board has created three specialist committees.
The Audit Committee assists the Board in its responsibility of monitoring the management of UCB and the UCB Group as a whole.
3 members (67% independent):
The Governance, Remuneration and Nomination Committee (GNCC) ensures that the appointment and re-election process is organized objectively and professionally and proposes the remuneration policy for non-executive Directors and executive managers.
5 members (80% independent):
The Scientific Committee assists the Board when reviewing the quality of UCB’s R&D science and its competitive standing. It assesses the strategy proposed by UCB’s management in R&D matters and communicates its recommendations to the Board.
3 members (100% independent):
Independent Director
Chair of the Board
Chair of the Audit Committee
First appointed in 2021
End of term in 2025
Director
Vice-chair of the Board
Member of the GNCC
First appointed in 2012
End of term in 2028
Executive Director
First appointed in 2014
End of term in 2026
Independent Director
First appointed in 2019
End of term in 2027
Independent Director
Member of the Audit Committee
First appointed in 2023
End of term in 2027
Independent Director
Member of the Scientific Committee
Chair of the GNCC
First appointed in 2014
End of term in 2026
Independent Director
Member of the GNCC
First appointed in 2016
End of term in 2028
Independent Director
Member of the Scientific Committee
First appointed in 2021
End of term in 2025
Director
First appointed in 2015
End of term in 2027
Director
Member of the Audit Committee
First appointed in 2014
End of term in 2026
Independent Director
Member of the GNCC
First appointed in 2016
End of term in 2028
Independent Director
Member of the GNCC
First appointed in 2024
End of term in 2028
Independent Director
Member of the Scientific Committee
First appointed in 2024
End of term in 2028
Independent Director
Chair of the Audit Committee
First appointed in 2024
End of term in 2028
Chief Executive Officer and
Chairman of the Executive Committee
Joined UCB in 2011
Appointed CEO in 2015
Executive Vice President
Chief Commercial Officer
Joined UCB in 1994
Appointed in 2015
Executive Vice President
Chief Financial Officer
Joined UCB in July 2020
Appointed in July 2020
Executive Vice President
Chief Human Resources Officer
Joined UCB in 2017
Appointed in 2017
Executive Vice President
Patient Evidence
Joined UCB in 2024
Appointed in 2024
Executive Vice President
Supply and Technology Solutions
Joined UCB in 2019
Appointed in 2019
Executive Vice President & Chief Scientific Officer
Joined UCB in 2004
Appointed in 2024
Executive Vice President
General Counsel
Joined UCB in 2023
Appointed in 2023